Related Experiment Video
Updated: Jul 28, 2025
06:28
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
8.4K
The Europa Uomo Patient Reported Outcome Study 2.0-Prostate Cancer Patient-reported Outcomes to Support Treatment
Lionne D F Venderbos1, Sebastiaan Remmers1, André Deschamps2
1Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
European Urology Focus
|June 2, 2023
Summary
The Europa Uomo Patient Reported Outcome Study 2.0 (EUPROMS 2.0) surveyed 3571 prostate cancer patients. Treatment impacts quality of life, affecting urinary incontinence, sexual function, fatigue, and insomnia.
Area of Science:
- Oncology
- Patient-Reported Outcomes
- Health Services Research
Background:
- The Europa Uomo Patient Reported Outcome Study 2.0 (EUPROMS 2.0) was initiated to amplify patient voices in prostate cancer (PCa) care.
- This study addresses the need for real-world data on the patient experience post-PCa treatment.
Purpose of the Study:
- To gather self-reported data on physical and mental well-being among PCa patients after treatment.
- To provide insights for future patients regarding the impact of PCa treatments.
- To inform shared decision-making processes in PCa care.
Main Methods:
- A cross-sectional survey (EUPROMS 2.0) was administered to PCa patients.
- Validated questionnaires including EQ-5D-5L, EORTC-QLQ-C30, EPIC-26, and SDM-Q-9 were utilized.
- Descriptive statistics analyzed demographic, clinical, and patient-reported outcome data.
Main Results:
- 3571 men from 30 countries completed the survey between October 2021 and January 2022.
- Active PCa treatments negatively impacted quality of life, particularly sexual function, fatigue, and insomnia.
- Radical prostatectomy was associated with lower urinary incontinence levels compared to active surveillance.
Conclusions:
- EUPROMS 2.0 successfully collected extensive patient experience data, highlighting key treatment side effects.
- Findings underscore the importance of addressing urinary incontinence, sexual function, fatigue, and insomnia in PCa survivorship.
- The study empowers patients by providing accessible information to enhance doctor-patient relationships and shared decision-making.
Related Concept Videos
01:21Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
01:20Disorders of the Male Reproductive System
481
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
481
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K